Clinical and economic analysis of empagliflozin therapy in patients with heart failure across the ejection fraction range

Aim. To evaluate the cost-effectiveness of empagliflozin therapy in patients with heart failure (HF) across ejection fraction (EF) range Russian Fe­­deration. Material and methods. An analysis cost HF management was carried out an analytical decision-making model built MS Excel, which makes it possible estimating costs from state position. Results. Taking into account direct adverse events, as well indirect costs, potential economic benefit use for 766028 low EF could be RUB 7,6-7,8 billion per year therapy, while 5790280 moderately reduced preserved — 27,6-29,6 therapy. The 664960 immediately after hospitalization exacerbation 1,4-1,6 allowing to prevent 69438 deaths 60822 repeated exacerbations HF. Conclusion. Empagliflozin is optimal regimen treatment entire range, both without type 2 diabetes, terms clinical efficacy feasibility.